Winston W Shen1,2. 1. Department of Psychiatry, Wan Fang Medical Center, Taipei Medical University, Taipei, Taiwan. 2. Department of Psychiatry, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Abstract
AIM: In this review, the author focused on anticraving therapy for alcohol use disorder (AUD) defined by DMS-5. A comprehensive review was carried out on the available published papers on anticraving drugs for treating AUD patients. METHODS: The author described all drugs with anticraving benefits for treating AUD patients approved by the Food and Drug Administration of the United States (US FDA) and European Medicines Agency of the European Union. Then, the commonly prescribed anticraving drugs and those under development were also described. RESULTS: The US FDA-approved anticraving drugs included acamprosate and naltrexone, and those approved by European Medicines Agency were gamma-hydroxybutyrate and nalmefene. The author also highlighted topiramate, gabapentin, ondansetron, LY196044, ifenprodil, varenicline, ABT-436, mifepristone, citicoline, and baclofen. The putative mechanisms of action of and the use in clinical practice of those anticraving drugs were also described. CONCLUSION: Although slowly developing, the field of anticraving drugs is getting into shape as a promising entity of a pharmaceutical class of drugs. Then, the author addressed on the underused issues of those recommended, and suggested anticraving drugs by the practice guideline of the American Psychiatric Association. The author urges that clinicians should be more "adventurous" in prescribing those promising drugs because benefits of those anticraving drugs are far-outweighing the possible side effects of anticraving drugs, or the harms of untreated AUD itself.
AIM: In this review, the author focused on anticraving therapy for alcohol use disorder (AUD) defined by DMS-5. A comprehensive review was carried out on the available published papers on anticraving drugs for treating AUD patients. METHODS: The author described all drugs with anticraving benefits for treating AUD patients approved by the Food and Drug Administration of the United States (US FDA) and European Medicines Agency of the European Union. Then, the commonly prescribed anticraving drugs and those under development were also described. RESULTS: The US FDA-approved anticraving drugs included acamprosate and naltrexone, and those approved by European Medicines Agency were gamma-hydroxybutyrate and nalmefene. The author also highlighted topiramate, gabapentin, ondansetron, LY196044, ifenprodil, varenicline, ABT-436, mifepristone, citicoline, and baclofen. The putative mechanisms of action of and the use in clinical practice of those anticraving drugs were also described. CONCLUSION: Although slowly developing, the field of anticraving drugs is getting into shape as a promising entity of a pharmaceutical class of drugs. Then, the author addressed on the underused issues of those recommended, and suggested anticraving drugs by the practice guideline of the American Psychiatric Association. The author urges that clinicians should be more "adventurous" in prescribing those promising drugs because benefits of those anticraving drugs are far-outweighing the possible side effects of anticraving drugs, or the harms of untreated AUD itself.
Authors: Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray Journal: Drugs Date: 2022-02-08 Impact factor: 9.546
Authors: Renata Pauluci; Ana Regina Noto; Daniela Fernandez Curado; Miguel Siqueira-Campos; Andréia Gomes Bezerra; José Carlos Fernandes Galduróz Journal: Front Psychiatry Date: 2022-04-08 Impact factor: 4.157
Authors: Ming-Fen Ho; Cheng Zhang; Lixuan Wei; Lingxin Zhang; Irene Moon; Jennifer R Geske; Michelle K Skime; Doo-Sup Choi; Joanna M Biernacka; Tyler S Oesterle; Mark A Frye; Marvin D Seppala; Victor M Karpyak; Hu Li; Richard M Weinshilboum Journal: Br J Pharmacol Date: 2022-02-08 Impact factor: 9.473